TY  - JOUR
AU  - Kolwelter, Julie
AU  - Kannenkeril, Dennis
AU  - Linz, Peter
AU  - Jung, Susanne
AU  - Nagel, Armin M
AU  - Bosch, Agnes
AU  - Ott, Christian
AU  - Bramlage, Peter
AU  - Nöh, Lisa
AU  - Schiffer, Mario
AU  - Uder, Michael
AU  - Achenbach, Stephan
AU  - Schmieder, Roland E
TI  - The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.
JO  - Clinical research in cardiology
VL  - 112
IS  - 1
SN  - 0300-5860
CY  - Berlin
PB  - Springer
M1  - DKFZ-2022-02629
SP  - 134-144
PY  - 2023
N1  - 2023 Jan;112(1):134-144
AB  - Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patients with CHF.In a double-blind, randomised (2:1), placebo-controlled, parallel-group, clinical trial, 74 patients with NYHA class II-III CHF and an ejection fraction of 49
KW  - Chronic heart failure (Other)
KW  - Empagliflozin (Other)
KW  - Magnetic resonance imaging (Other)
KW  - SGLT2 inhibitor (Other)
KW  - Sodium (Other)
KW  - Tissue sodium content (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36289063
DO  - DOI:10.1007/s00392-022-02119-7
UR  - https://inrepo02.dkfz.de/record/182408
ER  -